HANSOH PHARMA GRANTS REGENERON AN EXCLUSIVE LICENSE RIGHTS TO ITS INVESTIGATIONAL DUAL GLP-1/GIP RECEPTOR AGONIST HS-20094 June 2, 2025 - Hansoh Pharma grants Regeneron Pharmaceuticals an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, and Macau), to its investigational dual GLP-1/GIP receptor agonist
In reproductive clinics, controlled ovarian hyperstimulation is recommended for patients with DOR to rapidly obtain usable embryos
Disclaimer: If you require laser, see my nurses at Cutis Dermatology
GLP-1 receptor agonists mimic the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety
The following benefits are available to ALL BSH GLP-1 patients regardless of the path they select: MONTHLY COACHING to optimize your monthly dosing strategy, while decreasing side effects
Retinol, retinal and retinoic acid (RA) exert physiological functions with RA being the most biologically relevant